# GRAIL

**Source:** https://geo.sig.ai/brands/grail-genomics  
**Vertical:** Healthcare  
**Subcategory:** Liquid Biopsy Cancer Detection  
**Tier:** Growth  
**Website:** grail.com  
**Last Updated:** 2026-04-14

## Summary

GRAIL develops multi-cancer early detection Galleri test using cell-free DNA methylation to detect signals from 50+ cancer types in a single blood draw; spun off from Illumina in 2024; NHS-Galleri trial enrolling 140,000 participants in the UK.

## Company Overview

GRAIL is a healthcare company founded in 2016 as an Illumina spinout focused on developing multi-cancer early detection tests using liquid biopsy technology. The company's flagship product Galleri is a blood test that analyzes cell-free DNA methylation patterns to detect cancer signals from over 50 cancer types, many of which lack standard screening tests, enabling detection at early stages when treatment is most effective. GRAIL raised over $3.5B from investors including Amazon and Bristol Myers Squibb and was reacquired by Illumina in 2021 before being spun off again in 2024 as an independent public company following regulatory complications. Galleri has been launched commercially and is being evaluated in large clinical studies including the NHS-Galleri trial in the UK enrolling 140,000 participants. The company represents a transformative approach to oncology that could shift cancer care from reactive treatment toward proactive screening. GRAIL's technology addresses a massive unmet need given that the majority of cancers are diagnosed at late stages when outcomes are poor.

## Frequently Asked Questions

### What is GRAIL?
GRAIL develops Galleri, a multi-cancer early detection blood test that analyzes cell-free DNA to detect signals of 50+ cancer types from a single blood draw, enabling earlier intervention when treatment is most effective.

### How does Galleri work?
Galleri analyzes methylation patterns in cell-free DNA circulating in the blood to detect cancer-associated signals and identify the tissue of origin, allowing detection of many cancers that have no existing standard screening test.

### What large clinical studies is GRAIL conducting?
GRAIL is conducting the NHS-Galleri trial in the UK enrolling approximately 140,000 participants to evaluate whether multi-cancer early detection can reduce cancer mortality at population scale.

### What is GRAIL's Galleri test?
Galleri is GRAIL's multi-cancer early detection (MCED) blood test that screens for more than 50 types of cancer by analyzing circulating cell-free DNA (cfDNA) fragments in the blood, detecting cancer signals before symptoms appear and predicting the cancer's tissue of origin.

### How does Galleri's multi-cancer detection work scientifically?
Galleri uses next-generation sequencing and machine learning to analyze methylation patterns in cell-free DNA fragments circulating in the bloodstream. Cancer cells shed DNA with distinct methylation signatures, allowing the test to detect cancer signals and identify the likely tissue of origin.

### What is the current evidence for Galleri's clinical performance?
GRAIL has published data from the PATHFINDER and STRIVE studies demonstrating Galleri's ability to detect cancer signals across multiple cancer types with a low false-positive rate (about 0.5%), though sensitivity varies by cancer type and stage.

### Is Galleri covered by insurance?
As of 2025, Galleri is available primarily through physician order and direct pay, as Medicare and most commercial insurers have not yet established broad coverage. GRAIL is conducting the NHS-England Galleri trial to build the clinical evidence needed for broader coverage decisions.

### What was the attempted Illumina acquisition of GRAIL?
Illumina reacquired GRAIL in 2021 for approximately $8 billion, but was ordered by the FTC and the EU to divest GRAIL due to antitrust concerns about Illumina's control of DNA sequencing. GRAIL was subsequently separated from Illumina and relisted as an independent public company.

## Tags

startup, technology, healthtech, analytics, public, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*